Product Description
a urine derivated compound (Menopur, Ferring), which contains both LH and FSH. (Sourced from: https://clinicaltrials.gov/ct2/history/NCT03737253?V_1=View)
Mechanisms of Action: FSH Binder
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Brazil | Bulgaria | Chile | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | France | Germany | Hungary | Indonesia | Ireland | Italy | Latvia | Norway | Pakistan | Philippines | Portugal | Romania | Russia | Spain | Sweden | Tunisia | Turkey | United Arab Emirates | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SHOview | N/A |
Completed |
Ovarian Hyperstimulation Syndrome |
2014-05-01 |